REMEGEN(688331) 新浪财经·2025-04-22 02:05Core Viewpoint - The Hong Kong Innovation Drug Index (987018) has shown a strong upward trend, indicating a positive market sentiment towards biotech companies in the region, particularly in the innovative drug sector [1] Group 1: Market Performance - As of April 22, 2025, the Hong Kong Innovation Drug Index increased by 4.45%, with notable gains from individual stocks such as Rongchang Biotech (09995) up by 10.06%, Kangzhi Pharmaceutical (00867) up by 5.58%, and Lepu Biotech-B (02157) up by 5.05% [1] - The Hong Kong Innovation Drug ETF (159567) rose by 1.94%, marking its third consecutive increase, with a latest price of 1.21 yuan [1] - Over the past two weeks, the Hong Kong Innovation Drug ETF has accumulated a total increase of 4.96% [1] - The ETF experienced a turnover rate of 5.72% during the trading session, with a transaction volume of 72.48 million yuan [1] - The average daily transaction volume for the ETF over the past week was 531 million yuan, with a scale growth of 83.05 million yuan [1] Group 2: Industry Insights - Huaxin Securities highlighted that in areas such as antibodies, ADCs, and bispecific antibodies, Chinese biotech companies have established a technological advantage from the initial stages of research and development [1] - The industry is continuously exploring new targets and combinations, leading to an increasing proportion of globally leading or optimal innovations [1] - The domestic policy environment for innovative drugs is improving, with a focus on establishing a diversified payment system and refining the pricing mechanism for innovative drugs [1] - The release of overseas clinical data and the peak of external licensing are accelerating the realization of innovative value [1] - There is a growing emphasis on collaboration and product licensing abroad, with the value of technological platforms becoming more prominent [1]